ClinicalTrials.Veeva

Menu

Brain Ultrasound in the Weaning of External Ventricular Leads (ECHO-SD)

T

Toulouse University Hospital

Status

Unknown

Conditions

Hydrocephalus
Intracranial Hypertension

Treatments

Other: Measuring the size of the 3rd ventricle by ultrasound

Study type

Observational

Funder types

Other

Identifiers

NCT03531723
2018-A01219-46 (Other Identifier)
RC31/18/0178

Details and patient eligibility

About

External Ventricular Deviation (EDV) is a medical device that provides transient and controlled external drainage of cerebrospinal fluid (CSF). This device can also monitor intracranial pressure (ICP). SEV is an emergency measure indicated for acute hydrocephalus and / or intracranial hypertension (HTIC). Weaning from a DVE should be considered as soon as possible from the moment the patient's clinical condition allows it. There is no consensus on how to wean SEVs.

The main objective of this study is to evaluate inter and intraobserver reproducibility of the measurement of the 3rd ventricle size by ultrasound in patients receiving a DVE withdrawal test.

Full description

Ultrasound assessment of the ventricular system, including the size of the 3rd ventricle, can be used in severe traumatic brain injury. Ultrasound measurement of the size of the 3rd ventricle is used as a marker to monitor cerebral atrophy in neurodegenerative diseases such as multiple sclerosis (MS). There is good correlation between brain ultrasound and MRI and CT brain imaging to assess the size of the 3rd ventricle. Ultrasound measurement of the size of the 3rd ventricle has never been evaluated in weaning external ventricular leads.

Measuring the size of the 3rd ventricle by ultrasound could be an interesting monitoring technique during a SEV withdrawal trial to predict success or failure.

Weaning is usually based on a clamp test with more or less paraclinical clinical monitoring. The recurrence of hydrocephalus and / or HTIC defines a withdrawal failure of the drainage device.

The size of the 3rd ventricle evaluated by cerebral CT in a clamp test is found as a predictor of weaning failure of a DVE.

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient benefiting from a DVE, whatever the indication
  • Hospitalized in the neurosurgical resuscitation and neurosurgical intensive care units of Toulouse University Hospital
  • First DVE withdrawal test initiated by the doctor in charge of the patient
  • Major patient
  • Affiliated person or beneficiary of a social security scheme.
  • Expression of non-opposition by the participant or his / her confidant and the investigator (at the latest on the day of inclusion and before any examination required by the research).

Exclusion criteria

  • Absence of cerebral acoustic window
  • Patient with a ventriculoperitoneal (DVP) diversion before the DVE.
  • Antecedent surgery in the cerebral ventricular system.
  • Pregnant and lactating woman
  • Person under safeguard of justice
  • Nosocomial neuro-meningeal infection on untreated or treatment-emergent DVE

Trial contacts and locations

1

Loading...

Central trial contact

Timothée ABAZIOU, MD; Isabelle Olivier, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems